These findings suggest that elevated Grb10 expression may contribute to diabetic nephropathy via suppressing IGF-1/IGF-1R signaling pathways, thus serving a potential molecular target of catalpol for the treatment of diabetic nephropathy. Here, IGF1R is linked to diabetic kidney disease.